102 related articles for article (PubMed ID: 38722741)
1. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma.
Ye T; Mishra AK; Banday S; Li R; Hu K; Coleman MM; Shan Y; Chowdhury SR; Zhou L; Pak ML; Simone TM; Malonia SK; Zhu LJ; Kelliher MA; Green MR
Cell Rep; 2024 May; 43(5):114211. PubMed ID: 38722741
[TBL] [Abstract][Full Text] [Related]
2. Discovery platform for inhibitors of IgH gene enhancer activity.
Dolloff NG
Cancer Biol Ther; 2019; 20(4):571-581. PubMed ID: 30481117
[TBL] [Abstract][Full Text] [Related]
3. Addiction to c-MYC in multiple myeloma.
Holien T; Våtsveen TK; Hella H; Waage A; Sundan A
Blood; 2012 Sep; 120(12):2450-3. PubMed ID: 22806891
[TBL] [Abstract][Full Text] [Related]
4. Critical role of WNK1 in MYC-dependent early mouse thymocyte development.
Köchl R; Vanes L; Llorian Sopena M; Chakravarty P; Hartweger H; Fountain K; White A; Cowan J; Anderson G; Tybulewicz VL
Elife; 2020 Oct; 9():. PubMed ID: 33051000
[TBL] [Abstract][Full Text] [Related]
5. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
6. WNK1 Enhances Migration and Invasion in Breast Cancer Models.
Jaykumar AB; Jung JU; Parida PK; Dang TT; Wichaidit C; Kannangara AR; Earnest S; Goldsmith EJ; Pearson GW; Malladi S; Cobb MH
Mol Cancer Ther; 2021 Oct; 20(10):1800-1808. PubMed ID: 34253593
[TBL] [Abstract][Full Text] [Related]
7. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
8. MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.
Saha MN; Abdi J; Yang Y; Chang H
Oncotarget; 2016 Feb; 7(6):7149-60. PubMed ID: 26771839
[TBL] [Abstract][Full Text] [Related]
9. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma.
Lee HC; Wang H; Baladandayuthapani V; Lin H; He J; Jones RJ; Kuiatse I; Gu D; Wang Z; Ma W; Lim J; O'Brien S; Keats J; Yang J; Davis RE; Orlowski RZ
Br J Haematol; 2017 Apr; 177(1):80-94. PubMed ID: 28369725
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma.
Venkata JK; An N; Stuart R; Costa LJ; Cai H; Coker W; Song JH; Gibbs K; Matson T; Garrett-Mayer E; Wan Z; Ogretmen B; Smith C; Kang Y
Blood; 2014 Sep; 124(12):1915-25. PubMed ID: 25122609
[TBL] [Abstract][Full Text] [Related]
11. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
12. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
13. MYC addiction: a potential therapeutic target in MM.
Kuehl WM; Bergsagel PL
Blood; 2012 Sep; 120(12):2351-2. PubMed ID: 22996653
[TBL] [Abstract][Full Text] [Related]
14. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Harada T; Ohguchi H; Grondin Y; Kikuchi S; Sagawa M; Tai YT; Mazitschek R; Hideshima T; Anderson KC
Leukemia; 2017 Dec; 31(12):2670-2677. PubMed ID: 28490812
[TBL] [Abstract][Full Text] [Related]
15. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
16. The CREB1/WNK1 axis promotes the tumorigenesis of ovarian cancer via regulating HIF-1.
Ma Y; Zong H; Pan P; Shang H; Yang X
Exp Cell Res; 2024 May; 438(1):114006. PubMed ID: 38599542
[TBL] [Abstract][Full Text] [Related]
17. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members.
Gauduchon J; Gouilleux F; Maillard S; Marsaud V; Renoir JM; Sola B
Clin Cancer Res; 2005 Mar; 11(6):2345-54. PubMed ID: 15788686
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Novel c-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma.
Yao R; Xie Y; Sun X; Zhang M; Zhou J; Liu L; Gao J; Xu K
Drug Des Devel Ther; 2020; 14():3983-3993. PubMed ID: 33061303
[TBL] [Abstract][Full Text] [Related]
19. FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress.
Ronca R; Ghedini GC; Maccarinelli F; Sacco A; Locatelli SL; Foglio E; Taranto S; Grillo E; Matarazzo S; Castelli R; Paganini G; Desantis V; Cattane N; Cattaneo A; Mor M; Carlo-Stella C; Belotti A; Roccaro AM; Presta M; Giacomini A
Cancer Res; 2020 Jun; 80(11):2340-2354. PubMed ID: 32094301
[TBL] [Abstract][Full Text] [Related]
20. The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.
Ghazzaui N; Saintamand A; Issaoui H; Vincent-Fabert C; Denizot Y
Oncotarget; 2017 Jan; 8(4):7059-7067. PubMed ID: 27729620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
